RAVE
2010
Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis
In 197 patients with severe ANCA-associated vasculitis, rituximab was non-inferior for inducing remission compared with cyclophosphamide.
Result
- Absolute difference
- 11 points
The absolute difference is derived from the event rates.
Also reported: (non-inferior); superior in the relapsing subgroup.
- Subtopic
- ANCA vasculitis
- Design
- Double-blind, double-dummy RCT
- Relevance
- Practice-defining: a trial the guidelines cite as evidence.
- Source
- Stone JH, et al. N Engl J Med. 2010;363(3):221-232.doi 10.1056/NEJMoa0909905
Discussion & critique
Established rituximab as standard induction in ANCA vasculitis, sparing cyclophosphamide exposure.